RESUMO
Topical tacrolimus has been observed to induce granulomatous rosacea (GR) in prior case reports and series. In most cases, patients recover fully after withdrawing tacrolimus and initiating doxycycline or minocycline. Herein, we describe a case of severe GR, which required further therapy. Clinicians should be aware of this rare complication because of the frequent use of topical tacrolimus.
Assuntos
Antibacterianos/uso terapêutico , Rosácea/induzido quimicamente , Tacrolimo/efeitos adversos , Tetraciclina/uso terapêutico , Dermatite Atópica/tratamento farmacológico , Feminino , Humanos , Rosácea/tratamento farmacológico , Tacrolimo/uso terapêutico , Adulto JovemRESUMO
Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from a variety of cancers. Temozolomide is well tolerated, and the reported dermatologic side effects of this medication are limited. Here, the authors report the first case of an urticarial hypersensitivity reaction induced by temozolomide. As this drug will likely be increasingly utilized in the near future, it is important to be aware of its potential to cause adverse cutaneous manifestations.
